Switch theme
Sign up to access all valuation multiples
Bioneer Corp engages in the manufacture and sale of biotechnological products in South Korea. It offers deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits, DNA and ribonucleic acid (RNA) amplification products, human diagnostics kits, veterinary diagnostics kits, among others.
1992
n/a
Last FY Revenue $214M
Last FY EBITDA -$2.0M
$326M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Bioneer achieved revenue of $214M and an EBITDA of -$2.0M.
Bioneer expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioneer valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $214M | XXX | XXX | XXX |
| Gross Profit | XXX | $160M | XXX | XXX | XXX |
| Gross Margin | XXX | 75% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1% | XXX | XXX | XXX |
| EBIT | XXX | -$9.7M | XXX | XXX | XXX |
| EBIT Margin | XXX | -5% | XXX | XXX | XXX |
| Net Profit | XXX | -$15.0M | XXX | XXX | XXX |
| Net Margin | XXX | -7% | XXX | XXX | XXX |
| Net Debt | XXX | $22.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bioneer's stock price is KRW 16550 (or $12).
Bioneer has current market cap of KRW 427B (or $311M), and EV of KRW 449B (or $326M).
See Bioneer trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $326M | $311M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bioneer has market cap of $311M and EV of $326M.
Bioneer's trades at 1.5x EV/Revenue multiple, and -161.4x EV/EBITDA.
Equity research analysts estimate Bioneer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioneer's P/E ratio is not available.
See valuation multiples for Bioneer and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $311M | XXX | $311M | XXX | XXX | XXX |
| EV (current) | $326M | XXX | $326M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -161.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -33.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -20.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -16.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioneer's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Bioneer's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioneer's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bioneer and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioneer acquired XXX companies to date.
Last acquisition by Bioneer was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioneer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bioneer founded? | Bioneer was founded in 1992. |
| Where is Bioneer headquartered? | Bioneer is headquartered in South Korea. |
| Who is the CEO of Bioneer? | Bioneer's CEO is Mr. Han-Oh Park. |
| Is Bioneer publicy listed? | Yes, Bioneer is a public company listed on KRX. |
| What is the stock symbol of Bioneer? | Bioneer trades under 064550 ticker. |
| When did Bioneer go public? | Bioneer went public in 2005. |
| Who are competitors of Bioneer? | Similar companies to Bioneer include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Bioneer? | Bioneer's current market cap is $311M |
| Is Bioneer profitable? | Yes, Bioneer is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
